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Abstract
Multidrug-resistant bacteria arise mostly by the accumulation of plasmids and chromosomal mutations. Typically, these
resistant determinants are costly to the bacterial cell. Yet, recently, it has been found that, in Escherichia coli bacterial cells, a
mutation conferring resistance to an antibiotic can be advantageous to the bacterial cell if another antibiotic-resistance
mutation is already present, a phenomenon called sign epistasis. Here we study the interaction between antibiotic-
resistance chromosomal mutations and conjugative (i.e., self-transmissible) plasmids and find many cases of sign epistasis
(40%)—including one of reciprocal sign epistasis where the strain carrying both resistance determinants is fitter than the
two strains carrying only one of the determinants. This implies that the acquisition of an additional resistance plasmid or of
a resistance mutation often increases the fitness of a bacterial strain already resistant to antibiotics. We further show that
there is an overall antagonistic interaction between mutations and plasmids (52%). These results further complicate
expectations of resistance reversal by interdiction of antibiotic use.
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Introduction
Multidrug resistance is a major hurdle for modern medicine,
putting at risk commonplace medical practices [1] and the treatment
of infection by bacterial pathogens [2]. Bacteria can become resistant
by spontaneous mutation of chromosomal genes or through the
acquisition ofhorizontally mobile genetic elements[1]. In the absence
of antibiotics, resistance mutations are often deleterious and confer a
fitness cost to the cell [3,4,5,6]. It is logical to expect that, in the
absence of antibiotic selective pressure, resistant strains will be
outcompeted by the susceptible ones. Thus, a possible procedure to
eliminate resistance is to ban the use of an antibiotic. This policy has
been applied in different countries with varying results. For example,
a deliberate reduction in the prescription of macrolides in Finland,
resulted in a 50% decrease in the frequency of macrolide-resistant
group A streptococci [7]. However, in the UK, a 98% decrease in the
consumption of sulfonamides was accompanied by an increase of
6.2% in the frequency of sulfonamide resistance in Escherichia coli [8].
Clearly, there are other factors affecting the reversal to susceptibility.
For example, resistant-bacteria often gain second-site mutations that
ameliorate the fitness cost of resistance [3,4,9,10,11,12,13]. Some-
times, compensatory mutations even increase the level of resistance
itself [14,15].
The exchange of accessory genetic elements, in particular of
conjugative plasmids, is frequent [16,17,18] and can disseminate
genes among related and phylogenetically distant bacteria
[16,18,19]. In addition, conjugative plasmids are able to mobilize
other plasmids from a donor to a recipient cell [20]. Thus,
resistance genes can quickly spread among bacterial communities.
Plasmid-encoded resistance is generally the result of the activity of
efflux pumps, agent-modifying enzymes [3], or protection of the
antibiotic target [21].
Harboring mobile genetic elements generally creates a cost to
the host, associated with the replication and maintenance of the
genetic element and with the expression of its genes. Such cost has
been experimentally demonstrated in a number of resistance-
encoding plasmids [22,23,24,25,26].
A recent study of the interaction between resistance-determin-
ing chromosomal mutations, responsible for resistance to nalidixic
acid, rifampicin and streptomycin in E. coli, found that, in the
majority of the cases, the combined fitness cost of double resistance
is smaller than one would expect if they were independent [27].
Gene interaction, or epistasis, is generally accepted as being
relevant for the understanding of the evolution and dynamics of
complex genetic systems [28]. Epistasis can vary in strength and
form. When epistasis affects fitness, one can expect two possible
outcomes. A positive epistatic interaction has an antagonistic effect
on deleterious mutations. Thus, the double mutant has a higher
fitness than the expected sum of costs. Negative epistasis between
deleterious mutations creates a synergistic effect. Here, the double
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of epistasis gathered evidence for both antagonistic and synergistic
gene interaction. Positive epistasis between random deleterious
mutations has been experimentally detected in phage WX174 [29],
HIV-1 [30], RNA virus W6 [31], Salmonella typhimurium [32] and in
the yeast Saccharomyces cerevisiae [33]. Other studies have found no
evidence of epistatic interactions within the HIV-1 transcriptional
promoter [34], in RNA virus [35,36] and in S. cerevisiae [33], or
evidence that positive epistasis occurs as often as negative epistasis
in RNA virus [37] and in E. coli [38].
Here we focus on the interplay between conjugative plasmids
and chromosomal mutations in E. coli. In particular, we look at
how bacterial fitness is affected by genetic interactions between
plasmids and resistance mutations. First, we quantify the degree of
epistasis between five conjugative resistance plasmids (R124,
R831, R16, R702 and RP4, carrying between one and four
resistance genes and belonging to four different incompatibility
groups) and 10 mutant alleles of the housekeeping genes gyrA, rpoB
and rpsL, conferring resistance to nalidixic acid, rifampicin and
streptomycin, respectively. The plasmids were isolated from nature
and the resistance mutations are polymorphic in natural
populations of different species of bacteria [13]. These genes are
involved in different steps of the cell’s essential flow of information
from DNA to protein. Specifically, gyrA codes for DNA gyrase, an
enzyme involved in DNA replication. Nalidixic acid and other
quinolones inhibit DNA replication by binding to DNA gyrase and
resistance to this class of drugs arises from the prevention of this
binding. Rifampicin belongs to the rifamycin class of antibiotics
which bind to the b-subunit of RNA polymerase, coded by rpoB,
thereby inhibiting transcription. Mutations in rpsL, which codes for
ribosomal protein S12, interfere with translation and can produce
resistance to streptomycin by blocking the binding of this drug to
the ribosome 30S subunit. Secondly, using the same plasmids, we
estimate epistasis between pairwise combinations of conjugative
plasmids inside the same cell.
We find pervasive sign epistasis in the interaction between
resistance mutations and conjugative plasmids. This implies that
the acquisition of an additional resistance plasmid to the existing
chromosomal resistance or the appearance of a chromosomal
drug-resistance mutation in a bacterial cell already containing a
plasmid may ameliorate the initial fitness cost of resistance and
therefore complicate resistance reversal. We also observed an
overall positive level of epistasis between mutations and plasmids.
Both the chromosomal allele and the plasmid seem to contribute
to determine the nature of the epistatic interaction, although the
host genotype appears to have a more determinant effect. In
contrast, the interaction between plasmids exhibit sign epistasis
only once, and, despite the occurrence of several cases of
somewhat strong epistasis, on average it appears to be null.
Results
Interaction between antibiotic resistance mutations and
resistance plasmids
Pairwise epistasis, e, between loci A and B can be measured as
follows. Suppose that the wild-type strain contains alleles A and B.
If wAb and waB are the fitnesses of each of the single mutants
relative to the wild-type strain, and wab the relative fitness of the
double mutant, then multiplicative epistasis is given by:
e~wab{wAbwaB. To estimate epistasis between plasmids and
mutations, we defined these quantities in a similar way. If
w(A;plasmid) is the relative fitness of the strain with the wild-type
allele (A) and containing a plasmid, w(a;{)is the relative fitness of
the mutant strain (with A allele replaced by the a allele), and
w(a;plasmid) is the relative fitness of the strain containing both the
mutation (a allele) and the plasmid, then epistasis between a
plasmid and a chromosomal mutation becomes: e~w(a;plasmid){
w(A;plasmid)w(a;{).
Each conjugative plasmid was introduced in E. coli K12
MG1655 cells by conjugation. Then, we determined the fitness
cost due to the presence of each plasmid relative to plasmid-free E.
coli K12 MG1655 cells. This was performed using a competition
assay, in the absence of antibiotics (see Materials and Methods).
Fitness costs of plasmids span from 2.8% to 8% (Table S1).
The fitness cost imposed by ten different spontaneous antibiotic-
resistance mutations was previously determined in ref. [27]. Table
S2 presents the clones chosen from ref. [27] and the fitness costs of
these mutations. Fitness costs of mutations vary between 0.5% and
27.5% (Table S2) [27].
To screen for epistatic interactions between chromosomal
mutations and conjugative plasmids, we further constructed, by
conjugation, all possible 50 combinations between these ten
mutations and the five plasmids. Then we determined the fitness
for each of these 50 combinations.
We found that 52% of the interactions present positive epistasis
and only 8% present negative epistasis (Figure 1A). Figure 1A
additionally shows that the nature of the epistatic interaction is not
gene but allele specific. In fact, the conjugative plasmid influences
how a specific allele interacts with plasmid-borne resistance
determinants. This means that, depending on the plasmid, an
allele can display no epistasis, positive epistasis or negative
epistasis. For example, allele gyrA D87G exhibits no epistatic
interaction with plasmid R124, however the same allele displays
negative epistasis with plasmid R831 and positive epistasis with
plasmids R16, R702 and RP4 (Figure 1A). The same pattern
(allele specific nature of epistasis) had been observed for epistasis
between resistance chromosomal mutations [27]. Supporting the
pervasive nature of antagonistic interactions between mutations
and plasmids, the distribution of the e values (Figure 1B) has a
significant positive median (median=0.037, bootstrap 95% CI
[0.021; 0.065]). Figure S1 plots the observed fitness against the
fitness expected in the absence of epistasis (e=0).
Author Summary
Bacteria can become resistant to antibiotics by spontane-
ous mutation of chromosomal genes or through the
acquisition of horizontally mobile genetic elements, mainly
conjugative plasmids. Plasmid-borne resistance is wide-
spread among bacterial pathogens. Plasmids generally
entail a cost to the host, associated with the replication
and maintenance of the genetic element and with the
expression of its genes. Therefore, in the absence of
antibiotic, both plasmids and resistance mutations are
often deleterious and confer a fitness cost to the cell. Here
we studied epistatic interactions between five natural
conjugative plasmids and ten chromosomal mutations
conferring resistance to three types of antibiotics, making
a total of 50 different combinations of chromosomal
mutations and conjugative plasmids. We show that
sometimes plasmids confer an advantage to bacterial
strains carrying resistance mutations in their chromosome.
This occurs in 32% (16 out of 50) of tested combinations.
Furthermore, in 5 out of 50 plasmid-mutations combina-
tions studied (10%), we observed an increased fitness
when a plasmid-bearing bacterial cell acquires a drug-
resistant mutation. These examples of sign epistasis are
highly unexpected. This work explains, at least in part, how
multidrug resistance evolved so rapidly.
Epistasis between Drug-Resistance Determinants
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reconstructed five (double) combinations independently and in the
opposite direction from what we did before: gyrA S83L(R16), rpoB
I572F(R831), rpoB H526N(R16), rpoB R529H(R702), and rpsL
K43N(RP4). We constructed these five clones by transducting [27]
the antibiotic resistance mutation from our mutant E. coli strains
into the wild-type strain (E. coli K12 MG1655) already containing
the plasmid. Using this method we decreased the number of
generations involving the antibiotic-resistance mutation by a half
(because the plasmid was already there). In this way, we decrease
the probability of occurrence of compensatory mutations. We
measured the fitness of two independent clones corresponding to
Figure 1. Epistasis between antibiotic resistance mutations and conjugative plasmids. (A) Epistasis between mutations in genes gyrA,
rpoB and rpsL and conjugative resistance plasmids (positive epistasis in grey, negative in black and no epistasis in white). Sign epistasis is indicated
with ‘‘++’’. (B) Distribution of the epistasis values. Median is positive (0.037) with bootstrap 95% confidence interval [0.021; 0.065], showing an overall
level of positive epistasis between chromosomal resistance mutations and conjugative resistance plasmids. According to a Shapiro-Wilk W-test, the e
values do not follow a normal distribution (p=0.000968).
doi:10.1371/journal.pgen.1002181.g001
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fitness values are not significantly different from the ones obtained
using the previous method (Kruskal-Wallis, p.0.05). Four (gyrA
S83L(R16), rpoB I572F(R831), rpoB H526N(R16) and rpoB
R529H(R702)) of these five combinations correspond therefore
to cases of sign epistasis (Figure 1A). One combination (rpsL
K43N(RP4)) shows no interaction with these new independent
clones as observed before (Figure 1A). The fact that independent
clones exhibit the same fitness (and the same type of epistasis)
shows that our results are robust. To further strengthen this point,
we constructed two new independent clones of rpoB R529H(R702),
this time using yet a different method: by simultaneous
conjugation and transduction. The fitnesses of these clones were
again not significantly different from before (Kruskal-Wallis,
p.0.05).
Focusing on the resistance mutations, we notice that the mean
epistatic value significantly varies among them (Kruskal-Wallis
p=0.0016). Figure 2A shows that mutations rpoB R529H, rpsL
K88E and rpsL K43N exhibit positive and large e values. The
other mutations show lower mean e values (Mann-Whitney U-
Test, p=0.000002).
Figure 2B shows that there is a significant correlation between
the fitness cost created by a mutation and its mean epistatic value
(deviation from zero in absolute value) (Spearman p=0.006). In
other words, mutations with a more deleterious effect on the cell
tend to be more epistatic. This relationship had been initially
proposed after in silico studies of digital organisms and theoretical
modeling of RNA secondary structures [39]. Our results are in
accordance with previous experimental data from studies of
epistasis amongst antibiotic resistance alleles in E. coli [27], and
from a study of enzymes involved in gene expression and protein
synthesis in Pseudomonas aeruginosa [40].
Focusing on the conjugative plasmids, Figure 3A shows their
mean e values. There are no significant differences in the mean e
values between plasmids (Kruskal-Wallis p=0.676). This means
that, on average, all studied conjugative plasmids tend to interact
in the same way with chromosomal mutations. Moreover,
comparison between Figure 2A and Figure 3A seems to suggest
that the mutation (and not the plasmid) may be the major factor
determining the type and the strength of the epistatic interactions
we observed. In contrast to what was observed with the effect of
mutations on epistasis [27], there is no significant correlation
between the fitness cost created by a plasmid and its mean epistatic
value (Figure 3B – Spearman p=0.188). This may simply be due
to lack of power, as variation in plasmids cost is much smaller than
for mutations.
Sign epistasis
A specific mutation can be deleterious on a particular genetic
background and beneficial on others – a phenomenon known as
sign epistasis. Strikingly, we report that 40% of the combinations
between resistance chromosomal mutations and conjugative
plasmids present sign epistasis (Figure 1A, where ‘‘++’’ indicates
sign epistasis). These are cases where the strain carrying both
resistant determinants was fitter than the strain carrying only the
mutation or only the plasmid (Figure 4). One of the genotypes
(D87G(R16)) presents reciprocal sign epistasis [41], meaning that
the mutant D87G and harboring the R16 plasmid is fitter than
both the plasmid-free mutant and the plasmid-bearing strain
without the mutation (hence sensitive to nalidixic acid).
We found examples of sign epistasis in all resistance alleles and
all plasmids of this study, i.e. there was no plasmid nor mutation
where we did not find, at least one case of sign epistasis. This high
prevalence of positive epistasis is not a consequence of plasmid
transfer to the reference strain. The proportion of transconjugants
was monitored at stationary phase, when bacterial density is
higher than 10
9 cells per ml, and was found to be less than 3%
(Table S3). Also, computer simulations show that these plasmid
transfer events imply an error in the calculation of epistasis that is
less than 1%, hence less than the experimental error.
Another interesting aspect of our data is that, three out of the 50
combinations (plasmid+mutation) presented fitness costs not
significantly different from zero (t-test, p.0.05); these strains are
the following: rpsL K43R(R16), rpsL K43R(R831) and gyrA
D87G(R16).
Interaction between conjugative resistance plasmids
Finally, we measured epistasis between conjugative plasmids.
This is relevant because there have been several reports of
bacterial pathogens harboring multiple resistance plasmids
[42,43]. We constructed nine out of the 10 possible pairwise
combinations of the five plasmids (plasmids R702 and RP4 belong
to the same incompatibility group, thereby preventing the
construction of this double transconjugant). In this context,
epistasis was estimated as: e~w(plasmid1;plasmid2){w(plasmid1;-)
w({;plasmid2).
In this mathematical expression, w({;plasmid2) and w(plasmid1;{)
are the fitnesses of single-plasmid carrying strains relative to the
wild-type plasmid-free strain, and w(plasmid1;plasmid2) is the fitness of
the strain carrying both plasmids, relative to the same wild-type
plasmid-free strain.
Two different plasmids inside the same bacterial cell can
interact either antagonistically or synergistically (Figure 5A).
Epistatic interaction was found in 7 out of 9 (78%) strains. Positive
epistasis (antagonistic interaction) is nearly as frequent (4/9) as
negative epistasis (3/9). One out of nine pairwise combinations of
plasmids presented sign epistasis (‘‘++’’ in Figure 5A). Figure 5B
shows the distribution of e values for all pairwise combinations
of plasmids. On average, plasmid pairwise epistasis is close
to 0 (median =20.000830, bootstrap 95% CI [20.034690;
0.061360]). It is interesting to note that one of the plasmids, R16,
interacts antagonistically with all other plasmids, and also with
most mutations. This plasmid is also the most costly (Table S1).
Discussion
Our results show that 52% (26/50) of the combinations between
antibiotic resistance mutations and resistance conjugative plasmids
interact antagonistically. This is a remarkable result because the
fitness cost of these strains that carry both resistance determinants
is lower than the independent sum of the cost of each determinant.
Moreover, 20 out of these 26 antagonistic interactions (77%)
exhibit sign epistasis or reciprocal sign epistasis, also an
outstanding finding because it means that the fitness cost of
harboring both resistance determinants is lower than the fitness
cost of bearing one of them. In other words, an initially deleterious
antibiotic resistance mutation can become beneficial through the
acquisition of a transferable antibiotic resistant plasmid (16 cases);
likewise, an initially costly antibiotic resistant plasmid may become
beneficial through the acquisition of a mutation conferring
resistance to an additional antibiotic (5 cases). This adds up to
20 cases of sign epistasis because of one instance of reciprocal sign
epistasis. Last, but not least, three of the plasmid+mutation
combinations presented fitnesses not significantly different from
the fitness of the wild-type strain.
Positive epistasis has been shown to occur between resistance
alleles in multidrug resistant E. coli. [27], P. aeruginosa [44] and
Streptococcus pneumoniae [45]. Such phenomena reduce the fitness
Epistasis between Drug-Resistance Determinants
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Our study aimed to detect the putative occurrence of epistatic
interactions involving conjugative resistance plasmids. Such
knowledge may help predict how a bacterial population will
evolve after the introduction of plasmid-borne resistance determi-
nants through horizontal gene transfer.
Our data strikingly suggests the pervasive occurrence of sign
epistasis in the interaction between chromosomal antibiotic
resistance mutations and conjugative plasmids. Sign epistasis has
been shown to have the power to constrain protein adaptation by
limiting the number of possible mutational paths and is therefore
relevant to the understanding of multidrug resistance emergence
[46]. Moreover, bacterial adaptation to the cost of mutation-
determined resistance involves the acquisition of second-site
mutations that compensate the fitness cost of the original mutation
[10]. Thus, compensatory mutations are an example of sign
epistasis [3,10,11,46]. Our finding of pervasive sign epistasis with
conjugative plasmids is one of the worst possible scenarios for the
current efforts to eradicate resistance through antibiotic bans. Sign
epistasis allows strains carrying a resistance mutation and a
plasmid to exhibit higher fitness, thus being able of outcompeting
strains carrying only the mutation or the plasmid (depending on
the specific case). These results pinpoint the need for future studies
involving other plasmids and other resistances.
Also important in the context of antibiotic resistance is our
finding of the ubiquitous occurrence of positive epistasis between
resistance plasmids and chromosomal resistance mutations. If such
antagonistic interaction is a common phenomenon, then multi-
drug resistance determined by the simultaneous presence of
plasmid-borne and chromosomal determinants will not create such
a high fitness cost as one could predict based on the individual
costs. Hence, such multiresistant strains may be able to persist at
significant frequencies in populations where the antibiotic selective
pressure has been removed.
Figure 2. Mutation effect on the mean epistatic value. (A) Mean epistatic value for each mutation. Error bars indicate twice the standard error.
Note how the mean epistatic effect significantly differ between mutations (Kruskal-Wallis p=0.0016) (B) Mutations become increasingly epistatic as
their severity increases. Note how the mean absolute epistatic effect correlates with the fitness cost associated with each mutation (Spearman
p=0.006).
doi:10.1371/journal.pgen.1002181.g002
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survey for genes of the E. coli chromosome that are affected by the
presence of the conjugative F-plasmid [47]. Such study found 107
genes exhibiting epistatic effects with the F-plasmid. Although such
effect was not found for gyrA, rpoB and rpsL, other host genes
involved in information transfer were reported to be affected by
the presence of the F-plasmid [47]. Under the framework of the
complexity hypothesis, these interactions between plasmids and
informational genes (rpoB [48,49,50] and rpsL [51]) and a
topoisomerase (gyrA [52]) are expected, given their pleiotropic
interactions with other genes. For example, Schmitt et al. have
shown that certain rpoB, rpsL and gyrA alleles affect F-exclusion of
bacteriophage T7 [53]. In addition, Ozawa et al. [54] showed that
rpoB mutations interact with a plasmidic gene (in Enterococcus
faecalis). Similarly, gyrB may also interact with plasmids, eventually
leading to their elimination from cells [55]. In conclusion,
resistance genes present on plasmids are not necessarily respon-
sible for the epistatic interactions observed.
We also report here the occurrence of significant epistasis
between two types of conjugative plasmids within the same host.
This finding has relevance for clinical isolates exhibiting multidrug
resistance afforded by the co-existence of several plasmids, a
situation which appears to be relatively common [43]. Our data
indicates that, on average, epistasis between the conjugative
plasmids is close to zero. However, we do not believe that our
results suggest a tendency for no epistatic interactions between
conjugative plasmids. In fact, our near-zero median level of
epistasis between conjugative plasmids is the consequence of
having a similar frequency of somewhat strong positive and
negative epistatic interaction pairs. Our results may indicate that
plasmid interaction follows an all-or-nothing type of response
where the net epistatic effect is either strongly negative or strongly
positive. However, further studies should use a larger sample of
plasmids. Recently, in silico studies of E. coli and S. cerevisiae
metabolic networks have suggested that genes involved in essential
reactions tend to interact antagonistically, while negative epistasis
was mainly limited to non-essential gene pairs [56]. The accessory
nature of plasmids versus the essential role of gyrA, rpoB and rpsL in
information flow may explain why positive epistasis appears to be
more frequent in the interaction between chromosomal mutations
and a plasmid than between two types of plasmids.
Our finding of pervasive positive epistasis and, in particular, of
sign epistasis, between mutations and conjugative plasmids raises
serious concerns to the reversal of antimicrobial-drug resistance.
Plasmid-borne multidrug resistance is widespread in microbial
clinical, animal and environmental isolates. Dissemination is
facilitated by the conjugative plasmids’ ability to mobilize their
own transfer (and of other plasmids) from the original host to a
Figure 3. Plasmid effect on the mean epistatic value. (A) Mean epistatic value for each plasmid. Error bars indicate twice the standard error.
Note how the mean epistatic effect does not significantly differ between plasmids (Kruskal-Wallis p=0.6758). (B) Evidence for the lack of correlation
between the fitness cost associated with each plasmid and its mean epistatic value (Spearman p=0.188).
doi:10.1371/journal.pgen.1002181.g003
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phylogenetically distant organisms. Furthermore, it is known that
plasmids act as recruiting platforms for resistance genetic
determinants, many of them able to transpose between the
plasmid and the host chromosome (and vice-versa). Thus, and
given the widespread nature of horizontal gene transfer in
prokaryotes it has been suggested that microbes share a common
gene pool [57]. Therefore, we predict that plasmid-borne
resistance dissemination control through antibiotic bans is not
likely to be successful. We suggest that resistance reversal policies
must target plasmids vulnerabilities. Three approaches have been
suggested [58]: inhibition of plasmid conjugation, inhibition of
plasmid replication, and exploitation of plasmid-encoded toxin-
antitoxin systems.
Materials and Methods
Bacterial strains, plasmids, and growth conditions
We used five natural conjugative plasmids, R124, R702, R16,
R831, and RP4, kindly provided by the Institute for Health,
Environment and Safety of the Belgian Nuclear Research Centre.
Plasmid characteristics are listed in Table S1. We introduced these
plasmids in wild-type E. coli K12 MG1655 and in a set of 10
spontaneous antibiotic-resistant clones derived from the wild-type
strain (Table S2). These mutations have been previously mapped
to gyrA, rpoB and rpsL resulting in resistance to nalidixic acid,
rifampicin and streptomycin (ref. 27).
For the construction of bacterial strains with conjugative
plasmids, donors and recipients (either wild-type E. coli K12
MG1655 or strains shown in Table S2) were put together for
24 hours. All donor strains are auxotrophic for specific amino-
acids and/or unable to use maltose, due to deletions in essential
genes/operons, as indicated in chromosomal markers: Mal
2:
maltose; Trp
2: tryptophan; Met
2: methionine and Pro
2: proline.
Selection of transconjugants was performed in M9 minimal
medium (56.4 g/L M9 minimal salts, 2 mM magnesium sulfate,
4 g/l sugar (see bellow), 15 g/l agar), supplemented with the
appropriate antibiotics. If donors are auxotrophic (Table S4) for
two amino-acids (E. coli CM140 and E. coli CM597), transconju-
gants were selected on minimal medium plates containing glucose
and no amino-acids. Otherwise, we used maltose and tryptophan
(E. coli CM317, E. coli CM319, E. coli CM312). As a control we
confirmed that neither donors (due to auxotrophies or inability to
use maltose as carbon source) nor recipient (due to antibiotics
selecting for plasmidic resistance genes) grow on these plates.
Transduction was done with P1 bacteriophage, according to the
methods described by Trindade et al. [27].
In competition assays, we used E. coli K12 MG1655 Dara as
‘‘reference strain’’. Due to a deletion in the arabinose operon this
strain produces red colonies when grown in tetrazolium arabinose
(TA) indicator agar, allowing it to be distinguished from its
competitor, which produces white colonies. TA medium contains
1% peptone, 0.1% yeast extract, 0.5% sodium chloride, 1.5%
agar, 1% arabinose and 0.005% tetrazolium chloride.
All bacterial strains were grown in liquid Luria-Bertani (LB)
medium at 37uC with agitation. Solid media was obtained by the
addition of agar (15 g/l). For growth and transconjugant selection,
antibiotics were added as follows: 40 mg/ml of nalidixic acid,
100 mg/ml of rifampicin, 100 mg/ml of streptomycin, 20 mg/ml of
tetracycline, 100 mg/ml of kanamycin and 100 mg/ml of ampicillin.
Dilutions of cultures were done in MgSO4 0.01 M. All strains
were kept frozen in 15% glycerol stocks.
Figure 4. Sign epistasis between chromosomal mutations and conjugative plasmids. Sign epistasis occurs when the fitness of the strain
carrying both resistance determinants (black bars) is greater than the fitness of at least one of the strains carrying a single resistance determinant
(mutation – grey bars; or plasmid – white bars). The genotype D87G(R16) presents reciprocal sign epistasis [41]. Error bars represent twice the
standard error.
doi:10.1371/journal.pgen.1002181.g004
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Competition assays were performed to determine the fitness costof
the resistance determinants, either the plasmid carriage alone, the
coexistence of both plasmid and mutation or the carriage of two
plasmids. The method used has been previously described by ref.
[27]. The strains carrying resistance determinants were competed
againstasusceptiblereferencestrain,E. coli K12 MG1655 Dara, in an
approximate proportion of 1:1 and in the absence of antibiotic
selective pressure. (i) Both strains were grown in 10 ml of liquid LB
medium for 24 hours at 37uC with aeration. (ii) 50 mlo ft h ed i l u t i o n
10
24 of each strain was added to 50 ml screw-cap tubes containing
10 ml of liquid LB medium. (iii) Values of both strain’s initial ratio
were estimated by plating a dilution of the mixture in TA agar
medium. (iv) Competitions proceeded by a period of 24 hours at
37uC with aeration. (v) At the end of the competition, appropriate
dilutions were plated onto TA agar plates to obtain the final ratios of
both competitors. These competitions spanned about 19 to 22
bacterial generations. If a high fitness cost precluded the resistant
strain of being recovered in the TA plates, a smaller dilution was
plated onto minimal medium supplemented with arabinose, which
does not allow the growth of the reference strain. The fitness cost of
each strain – i.e. the selection coefficient, s, – was estimated as the per
generation difference in Malthusian parameters between the mutant
and the wild-type (rm and rw respectively): specifically, s~rm{rw~
log
m(T) 
m(0)
w(T) 
w(0)
"#
=g, where T is the final time and g is the total
number of generations from t=0 until t=T. Then, we discounted
the cost of the Dara marker [59]. The fitness cost was estimated as an
average of three independent competition assays.
Measurement of epistasis and statistical significance
As explained in the main text, epistasis between a mutation and
plasmid can be calculated as e~w(a;plasmid){w(A;plasmid)w(a;{),
Figure 5. Evidence for epistasis between conjugative plasmids. (A) Distribution of the types of epistatic interaction found between
conjugative plasmids (positive epistasis in grey, negative epistasis in black and no epistasis in white). ‘‘Inc’’ indicates a combination of incompatible
plasmids. The single case of sign epistasis is marked with ‘++’. (B) Distribution of the epistasis level, e, whose median is 20.00083 with bootstrap
confidence interval [20.035; 0.061], showing that there are several cases of strong positive and negative epistasis despite the near 0 median.
doi:10.1371/journal.pgen.1002181.g005
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type allele (A) and carrying the plasmid, w(a;{)is the relative fitness
of the mutant strain (with A allele replaced by the a allele), and
w(a;plasmid) is the relative fitness of the strain containing both the
mutation (a allele) and the plasmid. Similarly, we defined epistasis
between plasmids as e~w(plasmid1;plasmid2){w(plasmid1;-)w({;plasmid2),
where w({;plasmid2) and w(plasmid1;{) are the fitnesses of single-
plasmid strains relative to the wild-type plasmid-free strain, and
w(plasmid1;plasmid2) is the fitness of the strain carrying two types of
plasmids, relative to the same wild-type plasmid-free strain. Then,
the error (se) of the value of e is estimated by the method of error
propagation;
for pairwise combinations of mutation and plasmid:
se~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2
(a;plasmid)zs2
w(A;plasmid)w2
(a;{)zs2
(a;{)w2
(A;plasmid)
q
;
for pairwise combinations of plasmids:
se~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
s2
(plasmid1;plasmid2)zs2
w(plasmid1;{)w2
({;plasmid2)zs2
({;plasmid2)w2
(plasmid1;{)
q
:
If the value of e was within the calculated error, we considered
that the two resistance determinants (mutation and plasmid or
plasmid and plasmid) did not show significant epistasis (indicated
as white boxes labeled ‘‘no epistasis’’ in Figure 1A and Figure 5A).
From the distribution of values of e, provided in Figure 1B and
Figure 5B, we calculated the median value of e and its 95% CI by
bootstrap where we took 10 000 samples.
To test the presence of sign epistasis, we compared the fitness of
each strain carrying two resistance determinants (mutation and
plasmid or plasmid and plasmid) and its corresponding single
resistance-determinant strains. We used a Student t-test to assess if
the fitness of the double-resistance-determinants strain was higher
than the fitness of any of the single resistance-determinant strains.
Statistical analyses performed using software Statistica 9.0 and
MatLab R2009b. Computer simulations performed with Mathe-
matica 7.
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